Abstract:BCR-ABL kinase inhibition is an effective strategy for the treatment of chronic myeloid leukemia (CML). Herein, we report compound 3a-P1, bearing a difluoro-indene scaffold, as a novel potent pan-inhibitor against BCR-ABL mutants, including the most refractory T315I mutant. As the privileged (S)-isomer compared to its (R)-isomer 3a-P2, 3a-P1 exhibited potent antiproliferative activities against K562 and Ku812 CML cells and BCR-ABL and BCR-ABLT315I BaF3 cells, with IC50 values of 0.4, 0.1, 2.1, and 4.7 nM, respectively. 3a-P1 displayed a good safety profile in a battery of assays, including single-dose toxicity, hERG K+, and genotoxicity. It also showed favorable mice pharmacokinetic properties with a good oral bioavailability (32%), a reasonable half-life (4.61 h), and a high exposure (1386 h·ng/mL). Importantly, 3a-P1 demonstrated a higher potency than ponatinib in a mice xenograft model of BaF3 harboring BCR-ABLT315I. Overall, the results indicate that 3a-P1 is a promising drug candidate for the treatment of CML to overcome the imatinib-resistant T315I BCR-ABL mutation.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00082?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00082</a>.Synthesis of compounds 17a–e, crystal data for compound 29, SFC report for compounds 3a and 3b, and the determination of the absolute configuration of compound (S)-23 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00082/suppl_file/jm1c00082_si_001.pdf">PDF</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00082/suppl_file/jm1c00082_si_002.csv">CSV</a>)X-ray crystal structure data for compound 29 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00082/suppl_file/jm1c00082_si_003.cif">CIF</a>)This article has not yet been cited by other publications.

Expanding the Structural Diversity of Bcr-Abl Inhibitors: Hybrid Molecules Based on GNF-2 and Imatinib.

Expanding the structural diversity of Bcr-Abl inhibitors: Dibenzoylpiperazin incorporated with 1 H -indazol-3-amine

Discovery of Novel Bcr-Abl Inhibitors with Diacylated Piperazine As the Flexible Linker

Design, Synthesis, and Biological Evaluation of Trizole-Based Heteroaromatic Derivatives As Bcr-Abl Kinase Inhibitors.

Discovery of Novel Bcr–Abl Inhibitors Targeting Myristoyl Pocket and ATP Site

Synthesis and Biological Evaluation of Novel Aromatic-Heterocyclic Biphenyls As Potent Anti-Leukemia Agents

Discovery of Novel Bcr-AblT315I Inhibitors with Flexible Linker. Part 1: Confirmation Optimization of Phenyl-1H-indazol-3-amine As Hinge Binding Moiety.

Allosteric inhibitors of Bcr-abl–dependent cell proliferation

Integrating amino acids into Bcr-Abl inhibitors: design, synthesis, biological evaluation, and in silico studies

Design, Synthesis, and Biological Evaluation of Novel Bcr-AblT315I Inhibitors Incorporating Amino Acids As Flexible Linker

Structure optimization, synthesis and bioactivity evaluation of novel BCR-ABL tyrosine kinase inhibitor targeting T315I mutation

Synthesis and Docking Study of 2-Phenylaminopyrimidine Abl Tyrosine Kinase Inhibitors

Design, Synthesis and Biological Evaluation of Pyridin-3-Yl Pyrimidines As Potent Bcr-Abl Inhibitors

Biological Evaluation of 2-Methylpyrimidine Derivatives As Active Pan Bcr-Abl Inhibitors

Identification of Novel Inhibitors of BCR-ABL Tyrosine Kinase Via Virtual Screening

Discovery of a Candidate Containing an ( S )-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1 H -inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia

Design, synthesis and antitumor evaluation of 3-chloro-4 - (pyridin-2-ylmethoxy) aniline derivatives as BCR-ABL kinase

Rationally designed BCR-ABL kinase inhibitors for improved leukemia treatment via covalent and pro-/dual-drug targeting strategies

Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML)

In silico identification of novel kinase inhibitors targeting wild-type and T315I mutant ABL1 from FDA-approved drugs

The Novel Anticancer Agent JNJ-26854165 is Active in Chronic Myeloid Leukemic Cells with Unmutated BCR/ABL and T315I Mutant BCR/ABL Through Promoting Proteosomal Degradation of BCR/ABL Proteins